FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016454009> ?p ?o ?g. }

• W2016454009 endingPage "815" @default.
• W2016454009 startingPage "811" @default.
• W2016454009 abstract "Our objective was to evaluate in vitro and in vivo the effect of the combination of trabectedin (Yondelis, ET-743) and irinotecan (CPT-11) or its major metabolite SN-38 in a human rhabdomyosarcoma cell line. The schedule trabectedin (1 h) followed by irinotecan or SN-38 (24 h) and the opposite sequence (irinotecan or SN-38 24 h followed by trabectedin 1 h) were analyzed in a rhabdomyosarcoma cell line. In vivo studies were conducted with trabectedin and irinotecan at the doses of 0.2 and 20 mg/kg, respectively, simultaneously administered with a q4d x 3 schedule. In vitro studies indicated an overall additive effect [combination index (CI) relatively close to 1.0], with the former schedule slightly superior to the latter (at the IC50 effect levels: CI=0.89 versus 1.07). Neither transcription nor expression of DNA topoisomerase I was affected by trabectedin treatment. In vivo the therapeutic results of the combination were certainly more impressive: trabectedin and irinotecan combination caused a strong and long-lasting effect on tumor growth (tumor volume inhibition=89%, log10 cell kill=1.6), whereas each drug given as a single agent was only marginally active. The discrepancy between the in vitro and in vivo results suggests possible mechanisms involving host cells, other than tumor cells. The striking effects of the combination observed in vivo could be related to a combination of a direct cytotoxic and an anti-inflammatory indirect effect. The very marked and long-lasting effect of the trabectedin and irinotecan combination in vivo suggests a basis for a clinical evaluation in pediatric patients with rhabdomyosarcoma." @default.
• W2016454009 created "2016-06-24" @default.
• W2016454009 creator A5013056121 @default.
• W2016454009 creator A5016191595 @default.
• W2016454009 creator A5020206768 @default.
• W2016454009 creator A5020551727 @default.
• W2016454009 creator A5022280775 @default.
• W2016454009 creator A5030156200 @default.
• W2016454009 creator A5055703421 @default.
• W2016454009 creator A5080096851 @default.
• W2016454009 creator A5088126168 @default.
• W2016454009 date "2005-09-01" @default.
• W2016454009 modified "2023-10-05" @default.
• W2016454009 title "Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft" @default.
• W2016454009 cites W1987646951 @default.
• W2016454009 cites W1998786739 @default.
• W2016454009 cites W1999434056 @default.
• W2016454009 cites W2099134833 @default.
• W2016454009 cites W2115369099 @default.
• W2016454009 cites W2123302336 @default.
• W2016454009 cites W2138266786 @default.
• W2016454009 cites W2149067734 @default.
• W2016454009 cites W2153544919 @default.
• W2016454009 cites W2157598836 @default.
• W2016454009 doi "https://doi.org/10.1097/01.cad.0000172837.67766.6a" @default.
• W2016454009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16096428" @default.
• W2016454009 hasPublicationYear "2005" @default.
• W2016454009 type Work @default.
• W2016454009 sameAs 2016454009 @default.
• W2016454009 citedByCount "21" @default.
• W2016454009 countsByYear W20164540092013 @default.
• W2016454009 countsByYear W20164540092014 @default.
• W2016454009 countsByYear W20164540092016 @default.
• W2016454009 countsByYear W20164540092017 @default.
• W2016454009 countsByYear W20164540092019 @default.
• W2016454009 countsByYear W20164540092022 @default.
• W2016454009 crossrefType "journal-article" @default.
• W2016454009 hasAuthorship W2016454009A5013056121 @default.
• W2016454009 hasAuthorship W2016454009A5016191595 @default.
• W2016454009 hasAuthorship W2016454009A5020206768 @default.
• W2016454009 hasAuthorship W2016454009A5020551727 @default.
• W2016454009 hasAuthorship W2016454009A5022280775 @default.
• W2016454009 hasAuthorship W2016454009A5030156200 @default.
• W2016454009 hasAuthorship W2016454009A5055703421 @default.
• W2016454009 hasAuthorship W2016454009A5080096851 @default.
• W2016454009 hasAuthorship W2016454009A5088126168 @default.
• W2016454009 hasConcept C121608353 @default.
• W2016454009 hasConcept C126322002 @default.
• W2016454009 hasConcept C142724271 @default.
• W2016454009 hasConcept C147897179 @default.
• W2016454009 hasConcept C150903083 @default.
• W2016454009 hasConcept C185592680 @default.
• W2016454009 hasConcept C202751555 @default.
• W2016454009 hasConcept C207001950 @default.
• W2016454009 hasConcept C2778256501 @default.
• W2016454009 hasConcept C2778629024 @default.
• W2016454009 hasConcept C2780259306 @default.
• W2016454009 hasConcept C2780752271 @default.
• W2016454009 hasConcept C2780844630 @default.
• W2016454009 hasConcept C502942594 @default.
• W2016454009 hasConcept C526805850 @default.
• W2016454009 hasConcept C55493867 @default.
• W2016454009 hasConcept C71924100 @default.
• W2016454009 hasConcept C86803240 @default.
• W2016454009 hasConcept C98274493 @default.
• W2016454009 hasConceptScore W2016454009C121608353 @default.
• W2016454009 hasConceptScore W2016454009C126322002 @default.
• W2016454009 hasConceptScore W2016454009C142724271 @default.
• W2016454009 hasConceptScore W2016454009C147897179 @default.
• W2016454009 hasConceptScore W2016454009C150903083 @default.
• W2016454009 hasConceptScore W2016454009C185592680 @default.
• W2016454009 hasConceptScore W2016454009C202751555 @default.
• W2016454009 hasConceptScore W2016454009C207001950 @default.
• W2016454009 hasConceptScore W2016454009C2778256501 @default.
• W2016454009 hasConceptScore W2016454009C2778629024 @default.
• W2016454009 hasConceptScore W2016454009C2780259306 @default.
• W2016454009 hasConceptScore W2016454009C2780752271 @default.
• W2016454009 hasConceptScore W2016454009C2780844630 @default.
• W2016454009 hasConceptScore W2016454009C502942594 @default.
• W2016454009 hasConceptScore W2016454009C526805850 @default.
• W2016454009 hasConceptScore W2016454009C55493867 @default.
• W2016454009 hasConceptScore W2016454009C71924100 @default.
• W2016454009 hasConceptScore W2016454009C86803240 @default.
• W2016454009 hasConceptScore W2016454009C98274493 @default.
• W2016454009 hasIssue "8" @default.
• W2016454009 hasLocation W20164540091 @default.
• W2016454009 hasLocation W20164540092 @default.
• W2016454009 hasOpenAccess W2016454009 @default.
• W2016454009 hasPrimaryLocation W20164540091 @default.
• W2016454009 hasRelatedWork W1851544119 @default.
• W2016454009 hasRelatedWork W1990414540 @default.
• W2016454009 hasRelatedWork W1992222388 @default.
• W2016454009 hasRelatedWork W2007539997 @default.
• W2016454009 hasRelatedWork W2011909208 @default.
• W2016454009 hasRelatedWork W2015829835 @default.
• W2016454009 hasRelatedWork W2016454009 @default.
• W2016454009 hasRelatedWork W2101599998 @default.
• W2016454009 hasRelatedWork W2534069503 @default.

• next